[go: up one dir, main page]

SI2428508T1 - Diamino heterociklična karboksamidna spojina - Google Patents

Diamino heterociklična karboksamidna spojina

Info

Publication number
SI2428508T1
SI2428508T1 SI201031107T SI201031107T SI2428508T1 SI 2428508 T1 SI2428508 T1 SI 2428508T1 SI 201031107 T SI201031107 T SI 201031107T SI 201031107 T SI201031107 T SI 201031107T SI 2428508 T1 SI2428508 T1 SI 2428508T1
Authority
SI
Slovenia
Prior art keywords
carboxamide compound
heterocyclic carboxamide
diamino heterocyclic
diamino
compound
Prior art date
Application number
SI201031107T
Other languages
English (en)
Inventor
Itsuro Shimada
Kazuo Kurosawa
Takahiro Matsuya
Kazuhiko Iikubo
Yutaka Kondoh
Akio Kamikawa
Hiroshi Tomiyama
Yoshinori Iwai
Original Assignee
Astellas Pharma Inc.
Kotobuki Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2428508(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd. filed Critical Astellas Pharma Inc.
Publication of SI2428508T1 publication Critical patent/SI2428508T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SI201031107T 2009-05-08 2010-05-06 Diamino heterociklična karboksamidna spojina SI2428508T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009113936 2009-05-08
EP10772177.1A EP2428508B9 (en) 2009-05-08 2010-05-06 Diamino heterocyclic carboxamide compound
PCT/JP2010/057751 WO2010128659A1 (ja) 2009-05-08 2010-05-06 ジアミノへテロ環カルボキサミド化合物

Publications (1)

Publication Number Publication Date
SI2428508T1 true SI2428508T1 (sl) 2016-04-29

Family

ID=43050157

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031107T SI2428508T1 (sl) 2009-05-08 2010-05-06 Diamino heterociklična karboksamidna spojina
SI201031651T SI3009428T1 (sl) 2009-05-08 2010-05-06 Diamino heterociklična karboksamidna spojina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201031651T SI3009428T1 (sl) 2009-05-08 2010-05-06 Diamino heterociklična karboksamidna spojina

Country Status (28)

Country Link
US (2) US8969336B2 (sl)
EP (2) EP2428508B9 (sl)
JP (1) JP5364159B2 (sl)
KR (1) KR101614572B1 (sl)
CN (1) CN102421761B (sl)
AU (1) AU2010245545B2 (sl)
BR (1) BRPI1011838B8 (sl)
CA (1) CA2760061C (sl)
CY (3) CY1117546T1 (sl)
DK (2) DK2428508T3 (sl)
ES (2) ES2667706T3 (sl)
FR (1) FR20C1003I2 (sl)
HR (2) HRP20151435T8 (sl)
HU (3) HUE038515T2 (sl)
IL (1) IL216132A (sl)
LT (2) LT3009428T (sl)
LU (1) LUC00147I2 (sl)
MX (1) MX2011011875A (sl)
NL (1) NL301028I2 (sl)
NO (2) NO3009428T3 (sl)
PL (2) PL2428508T3 (sl)
PT (2) PT2428508E (sl)
RS (2) RS57045B1 (sl)
SI (2) SI2428508T1 (sl)
SM (2) SMT201800237T1 (sl)
TW (1) TWI484961B (sl)
WO (1) WO2010128659A1 (sl)
ZA (1) ZA201108642B (sl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
US20130317029A1 (en) * 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
SG2014012728A (en) 2011-08-23 2014-06-27 Foundation Medicine Inc Novel kif5b-ret fusion molecules and uses thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
SG10201601352UA (en) 2011-11-23 2016-03-30 Portola Pharm Inc Pyrazine kinase inhibitors
ME02648B (me) * 2012-01-17 2017-06-20 Astellas Pharma Inc Jedinjenje pirazin karboksamida
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
KR102156398B1 (ko) * 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3060550B1 (en) * 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
KR20160093675A (ko) * 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3103453B1 (en) * 2014-02-04 2020-04-01 Astellas Pharma Inc. Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
HRP20230253T1 (hr) * 2015-07-03 2023-04-28 Astellas Pharma Inc. Stabilna farmaceutska kompozicija za oralnu administraciju
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US10744134B2 (en) 2015-11-04 2020-08-18 Astellas Pharma Inc. Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
CN106083821B (zh) * 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20200013683A (ko) 2017-05-17 2020-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 오피오이드에 의한 통증 치료 개선용 ｆｌｔ3 저해제
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3741753A4 (en) * 2018-03-28 2021-03-31 Shenzhen TargetRx, Inc. SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND COMPOSITION CONTAINING THE COMPOUND AND ITS USE
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020063856A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
FI3870579T3 (fi) * 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
WO2020184670A1 (ja) 2019-03-13 2020-09-17 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
US12178814B2 (en) 2019-04-03 2024-12-31 Astellas Pharma Inc. Pharmaceutical composition
CN115380024B (zh) * 2020-03-30 2024-03-15 南京明德新药研发有限公司 二氮杂螺吡喃化合物的晶型
CN111423387B (zh) * 2020-05-11 2022-03-08 苏州康纯医药科技有限公司 一种Gilteritinib关键中间体的制备方法
EP4159731A4 (en) * 2020-06-01 2024-06-26 Wigen Biomedicine Technology (Shanghai) Co., Ltd. New pyrazine compound
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN112225703B (zh) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
WO2022078305A1 (zh) * 2020-10-12 2022-04-21 四川海思科制药有限公司 一种杂环衍生物及其在医药上的应用
WO2023027966A1 (en) * 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
JP2025509598A (ja) * 2022-03-14 2025-04-11 パーデュー・リサーチ・ファウンデーション 脾臓チロシンキナーゼ阻害薬、組成物、および使用の方法
WO2023225005A1 (en) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
CN115124590B (zh) * 2022-07-05 2024-10-22 武汉大学中南医院 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075113A1 (en) 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
WO2000076980A1 (en) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
WO2008016660A2 (en) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Imidazoacridine compounds for treating leukemias
WO2008024974A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
PT2091918E (pt) 2006-12-08 2014-11-24 Irm Llc Compostos e composições como inibidores de proteína cinase
US20100144706A1 (en) 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
EP2183225A1 (en) 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009020990A1 (en) 2007-08-08 2009-02-12 Smithkline Beecham Corporation 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
JP5501234B2 (ja) 2007-09-28 2014-05-21 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピロロ−ピリミジン誘導体、これらの調製方法およびキナーゼ阻害剤としてのこれらの使用
US20090270418A1 (en) 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2271645A1 (en) 2008-04-07 2011-01-12 Irm Llc Compounds and compositions as kinase inhibitors
KR101238585B1 (ko) 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Also Published As

Publication number Publication date
TW201105326A (en) 2011-02-16
BRPI1011838A2 (pt) 2018-02-06
RU2011149799A (ru) 2013-06-20
TWI484961B (zh) 2015-05-21
LTPA2020002I1 (lt) 2020-02-10
HUE026647T2 (en) 2016-07-28
EP2428508A1 (en) 2012-03-14
SMT201800237T1 (it) 2018-09-13
PL2428508T3 (pl) 2016-05-31
MX2011011875A (es) 2011-12-08
CN102421761A (zh) 2012-04-18
CA2760061A1 (en) 2010-11-11
EP2428508A4 (en) 2012-11-28
HUS2000005I1 (hu) 2020-03-30
HRP20151435T1 (hr) 2016-03-25
FR20C1003I2 (fr) 2020-12-04
CA2760061C (en) 2017-02-28
JP5364159B2 (ja) 2013-12-11
HRP20151435T8 (hr) 2016-07-01
HUS000511I2 (hu) 2021-03-29
HUE038515T2 (hu) 2018-10-29
LUC00147I1 (sl) 2020-02-10
KR20120007523A (ko) 2012-01-20
ZA201108642B (en) 2013-02-27
HK1219105A1 (en) 2017-03-24
NO2020001I1 (no) 2020-01-16
DK3009428T3 (en) 2018-03-26
EP3009428A1 (en) 2016-04-20
SI3009428T1 (sl) 2018-04-30
PL3009428T3 (pl) 2018-07-31
BRPI1011838B8 (pt) 2021-05-25
US8969336B2 (en) 2015-03-03
CY2020004I2 (el) 2020-05-29
IL216132A (en) 2015-10-29
ES2667706T3 (es) 2018-05-14
US20140371196A1 (en) 2014-12-18
CN102421761B (zh) 2014-06-18
NL301028I2 (nl) 2020-04-15
WO2010128659A1 (ja) 2010-11-11
RS57045B1 (sr) 2018-05-31
CY2020004I1 (el) 2020-05-29
HRP20180368T1 (hr) 2018-04-06
PT3009428T (pt) 2018-04-02
LT3009428T (lt) 2018-04-10
NO3009428T3 (sl) 2018-07-21
EP2428508B1 (en) 2015-12-16
IL216132A0 (en) 2012-01-31
CY1117546T1 (el) 2017-04-26
CY1120367T1 (el) 2019-07-10
US9487491B2 (en) 2016-11-08
AU2010245545A1 (en) 2011-11-03
LUC00147I2 (sl) 2021-02-12
KR101614572B1 (ko) 2016-04-21
RU2526253C2 (ru) 2014-08-20
ES2559230T3 (es) 2016-02-11
LTC2428508I2 (lt) 2020-12-28
NL301028I1 (nl) 2020-01-22
US20120040968A1 (en) 2012-02-16
AU2010245545B2 (en) 2014-09-11
EP2428508B9 (en) 2016-04-20
PT2428508E (pt) 2016-02-29
JPWO2010128659A1 (ja) 2012-11-01
BRPI1011838B1 (pt) 2021-03-16
RS54552B1 (sr) 2016-06-30
EP3009428B1 (en) 2018-02-21
DK2428508T3 (en) 2016-02-01
SMT201600075B (it) 2016-04-29
FR20C1003I1 (sl) 2020-03-20

Similar Documents

Publication Publication Date Title
CY2020004I2 (el) Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου
ZA201202106B (en) Substituted amide compound
ZA201006511B (en) Heterocyclic compound
IL216973A0 (en) Heterocyclic compounds and their uses
IL218078A0 (en) Heterocyclic compounds and uses thereof
ZA201203137B (en) Substituted benzamide derivatives
IL221442A0 (en) Heterocyclic compound
IL208203A0 (en) Heterocyclic derivatives
ZA201300950B (en) Heterocyclic compound
IL217183A0 (en) Benzamide derivatives
ZA201106792B (en) Amide derivative
ZA201200415B (en) Amide derivative
GB0921210D0 (en) Novel heterocyclic derivatives
GB0919816D0 (en) Heterocyclic compounds
GB0919817D0 (en) Heterocyclic compounds
GB0810243D0 (en) Amide derivatives